文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

10 kHz高频脊髓电刺激治疗痛性糖尿病神经病变:多中心随机对照试验设计(SENZA-PDN)

High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN).
PubMed 文献 · Trials · 2020-01-15

SENZA-PDN是一项前瞻性、多中心、随机对照试验,计划纳入216例痛性糖尿病神经病变(PDN)受试者,按1:1随机接受10 kHz脊髓电刺激(SCS)联合常规医疗管理(CMM)或单纯CMM,随访24个月。主要终点为3个月时应答率(疼痛缓解≥50%)与安全性率,旨在评估10 kHz SCS对CMM难治性PDN的临床疗效、生活质量改善及成本效益。

要点

  • 10 kHz SCS联合CMM与单纯CMM对比,主要终点为3个月应答率(疼痛缓解≥50%)和安全性率。
  • 纳入标准包括PDN症状≥12个月、下肢平均疼痛强度VAS≥5 cm(0–10 cm量表)。
  • 排除标准包括大溃疡或坏疽性溃疡,或上肢/上下肢平均疼痛强度VAS≥3 cm。

核心结论

  • 该研究旨在确定10 kHz SCS是否能改善CMM难治性PDN患者的临床结局和生活质量,并具有成本效益。

研究设计与样本

  • 前瞻性、多中心、随机对照试验(SENZA-PDN),计划纳入216例PDN受试者,按1:1随机分组,随访24个月。

主要发现

  • 原文未报告研究结果,仅描述研究设计。

关键数值与推荐

  • 主要终点为3个月时比较组间应答率(疼痛缓解≥50%)和安全性率。
  • 纳入标准:PDN症状至少12个月;下肢平均疼痛强度VAS至少5 cm(0–10 cm量表);适合SCS的候选者。
  • 排除标准:大溃疡或坏疽性溃疡;上肢或上下肢平均疼痛强度VAS至少3 cm。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Painful diabetic neuropathy (PDN), a debilitating and progressive chronic pain condition that significantly impacts quality of life, is one of the common complications seen with long-standing diabetes mellitus. Neither pharmacological treatments nor low-frequency spinal cord stimulation (SCS) has provided significant and long-term pain relief for patients with PDN. This study aims to document the value of 10-kHz SCS in addition to conventional medical management (CMM) compared with CMM alone in patients with refractory PDN. METHODS: In a prospective, multicenter, randomized controlled trial (SENZA-PDN), 216 subjects with PDN will be assigned 1:1 to receive 10-kHz SCS combined with CMM or CMM alone after appropriate institutional review board approvals and followed for 24 months. Key inclusion criteria include (1) symptoms of PDN for at least 12 months, (2) average pain intensity of at least 5 cm-on a 0- to 10-cm visual analog scale (VAS)-in the lower limbs, and (3) an appropriate candidate for SCS. Key exclusion criteria include (1) large or gangrenous ulcers or (2) average pain intensity of at least 3 cm on VAS in the upper limbs or both. Along with pain VAS, neurological assessments, health-related quality of life, sleep quality, and patient satisfaction will be captured. The primary endpoint comparing responder rates (≥50% pain relief) and safety rates between the treatment groups will be assessed at 3 months. Several secondary endpoints will also be reported on. DISCUSSION: Enrollment commenced in 2017 and was completed in 2019. This study will help to determine whether 10-kHz SCS improves clinical outcomes and health-related quality of life and is a cost-effective treatment for PDN that is refractory to CMM. TRIAL REGISTRATION: ClincalTrials.gov identifier: NCT03228420 (registered 24 July 2017).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mekhail NA, Argoff CE, Taylor RS, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials. 2020. PMID: 31941531. doi:10.1186/s13063-019-4007-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。